

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

ANTIGENICS INC /DE/  
Form 8-K  
June 05, 2006

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

June 5, 2006  
Date of Report (Date of earliest event reported)

-----  
ANTIGENICS INC  
(Exact name of registrant as specified in its charter)

-----  
DELAWARE    000-29089    06-1562417  
(State or other jurisdiction                          (Commission    (IRS Employer  
of incorporation)    File Number)    Identification No.)

630 Fifth Avenue, Suite 2100  
New York, NY 10111    10111  
(Address of principal executive offices)    (Zip Code)

212-994-8200  
(Registrant's telephone number, including area code)

-----  
Check the appropriate box below if the Form 8-K filing is intended to  
simultaneously satisfy the filing obligation of the registrant under any of the  
following provisions (see General Instruction A.2. below):

- [ ] Written communications pursuant to Rule 425 under the Securities Act (17  
CFR 230.425)
- [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR  
240.14a-12)
- [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the  
Exchange Act (17 CFR 240.14d-2(b))
- [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the  
Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

On June 5, 2006, Antigenics Inc. announced updated findings from its  
Phase 3 clinical trial of the company's investigational cancer vaccine  
Oncophage(R) (vitespen; formerly HSPPC-96) in metastatic melanoma. The  
full text of the press release issued in connection with the

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibit is furnished herewith:

99.1 Press Release dated June 5, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANTIGENICS INC.

Date: June 5, 2006

By: /s/ Garo H. Armen, Ph.D.

-----  
Garo H. Armen, Ph.D.  
Chairman and Chief Executive Officer

EXHIBIT INDEX

Exhibit No. -----	Description of Exhibit -----
99.1	Press Release dated June 5, 2006